This study highlights the importance of GIIA sPLA2, establishing this enzyme as a factor that leads to severe COVID-19 morbidity and mortality, and suggesting it as a therapeutic target to prevent COVID-19 mortality. The gene discussed is PLA2G2A; the disease is COVID-19.